Showing 161 - 180 results of 25,875 for search '(( 50 ((((mean decrease) OR (greater decrease))) OR (nn decrease)) ) OR ( 19 a decrease ))', query time: 0.57s Refine Results
  1. 161

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  2. 162

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  3. 163
  4. 164
  5. 165

    Table1_Satisfaction With Governmental Risk Communication Both Increases and Decreases COVID-19 Mitigation Behaviours.docx by Darrick Evensen (13757068)

    Published 2023
    “…</p><p>Results: Structural equation modelling reveals that whilst perceptions of effective risk communication directly increase behaviours that mitigate COVID-19 health risks, these same perceptions indirectly decrease behaviour frequency via a mediated relationship with societal risk perceptions.…”
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174

    Data_Sheet_1_Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity.docx by Chantal C. Clark (10684632)

    Published 2021
    “…</p><p>Conclusion: We observed an association between the use of preexisting thromboprophylaxis and a decreased risk of TE during COVID-19. This suggests that these therapies are beneficial for coping with COVID-19 associated hypercoagulability. …”
  15. 175

    Determinants of decrease in COVID-19 immunity among vaccinated patients over a 6-month period using univariate analysis and multivariable logistic regression models. by Dalal Nour (18530615)

    Published 2024
    “…<p>Determinants of decrease in COVID-19 immunity among vaccinated patients over a 6-month period using univariate analysis and multivariable logistic regression models.…”
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180